$CORT
Corcept Therapeutics Inc

2020 Q4 Form 10-Q Financial Statement

#000162828020015376 Filed on November 03, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $85.74M $86.33M $87.90M
YoY Change -2.46% 5.92% 31.52%
Cost Of Revenue $1.250M $1.216M $1.440M
YoY Change -13.19% -16.2% -8.86%
Gross Profit $84.48M $85.11M $86.46M
YoY Change -2.29% 6.32% 32.5%
Gross Profit Margin 98.54% 98.59% 98.37%
Selling, General & Admin $25.70M $26.52M $27.13M
YoY Change -5.27% 9.4% 25.83%
% of Gross Profit 30.42% 31.16% 31.38%
Research & Development $28.28M $33.87M $24.31M
YoY Change 16.33% 48.52% 29.38%
% of Gross Profit 33.47% 39.79% 28.12%
Depreciation & Amortization $100.0K $0.00 $200.0K
YoY Change -50.0% -100.0%
% of Gross Profit 0.12% 0.0% 0.23%
Operating Expenses $53.98M $60.39M $51.44M
YoY Change 4.94% 28.36% 27.48%
Operating Profit $30.50M $24.72M $35.02M
YoY Change -12.9% -25.1% 40.63%
Interest Expense $300.0K $620.0K $1.440M
YoY Change -79.17% -54.07% 38.46%
% of Operating Profit 0.98% 2.51% 4.11%
Other Income/Expense, Net $622.0K
YoY Change -53.86%
Pretax Income $30.81M $25.34M $36.46M
YoY Change -15.5% -26.23% 40.56%
Income Tax $4.810M $3.700M $7.080M
% Of Pretax Income 15.61% 14.6% 19.42%
Net Earnings $25.99M $21.63M $29.38M
YoY Change -11.53% -17.9% 33.5%
Net Earnings / Revenue 30.32% 25.05% 33.43%
Basic Earnings Per Share $0.22 $0.19 $0.26
Diluted Earnings Per Share $0.20 $0.17 $0.24
COMMON SHARES
Basic Shares Outstanding 116.2M shares 115.7M shares 114.3M shares
Diluted Shares Outstanding 124.5M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $440.7M $428.8M $276.0M
YoY Change 59.69% 85.15% 33.47%
Cash & Equivalents $76.19M $30.56M $31.27M
Short-Term Investments $364.5M $398.2M $244.7M
Other Short-Term Assets $6.700M $7.900M $6.000M
YoY Change 11.67% 1.28% -22.08%
Inventory $4.910M $4.817M $5.424M
Prepaid Expenses
Receivables $26.20M $21.96M $19.93M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $478.5M $463.5M $307.4M
YoY Change 55.68% 73.39% 29.79%
LONG-TERM ASSETS
Property, Plant & Equipment $1.675M $1.311M $1.050M
YoY Change 59.52% 6.85% 60.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $36.20M $15.40M $39.40M
YoY Change -8.12% -56.37%
Other Assets $5.000M $5.010M $3.448M
YoY Change 45.01% 3240.0% 6796.0%
Total Long-Term Assets $93.23M $70.63M $105.0M
YoY Change -11.17% -29.16% 40.17%
TOTAL ASSETS
Total Short-Term Assets $478.5M $463.5M $307.4M
Total Long-Term Assets $93.23M $70.63M $105.0M
Total Assets $571.7M $534.1M $412.3M
YoY Change 38.66% 45.53% 32.28%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.55M $6.510M $7.537M
YoY Change 40.03% 9.65% -8.82%
Accrued Expenses $21.19M $18.97M $23.27M
YoY Change -8.95% -12.04% -2.17%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $47.49M $43.05M $38.84M
YoY Change 22.28% 32.88% 9.19%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $1.400M $2.300M
YoY Change -60.87% 366.67% 1050.0%
Total Long-Term Liabilities $900.0K $1.400M $2.300M
YoY Change -60.87% 366.67% 1050.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $47.49M $43.05M $38.84M
Total Long-Term Liabilities $900.0K $1.400M $2.300M
Total Liabilities $48.39M $44.45M $41.13M
YoY Change 17.66% 36.14% 14.85%
SHAREHOLDERS EQUITY
Retained Earnings $82.46M $56.46M -$23.56M
YoY Change -450.06% -206.66% -79.99%
Common Stock $516.3M $496.6M $457.2M
YoY Change 12.92% 11.17% 9.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares 5.300M shares
Shareholders Equity $523.3M $489.7M $371.2M
YoY Change
Total Liabilities & Shareholders Equity $571.7M $534.1M $412.3M
YoY Change 38.66% 45.53% 32.28%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income $25.99M $21.63M $29.38M
YoY Change -11.53% -17.9% 33.5%
Depreciation, Depletion And Amortization $100.0K $0.00 $200.0K
YoY Change -50.0% -100.0%
Cash From Operating Activities $35.10M $30.40M $48.40M
YoY Change -27.48% -21.04% 124.07%
INVESTING ACTIVITIES
Capital Expenditures -$400.0K -$700.0K -$100.0K
YoY Change 300.0% 133.33% 0.0%
Acquisitions
YoY Change
Other Investing Activities $11.70M -$63.60M -$61.80M
YoY Change -118.93% 17.78% 3535.29%
Cash From Investing Activities $11.20M -$64.30M -$62.00M
YoY Change -118.06% 18.42% 3344.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -700.0K 5.900M -100.0K
YoY Change 600.0% 118.52% -99.17%
NET CHANGE
Cash From Operating Activities 35.10M 30.40M 48.40M
Cash From Investing Activities 11.20M -64.30M -62.00M
Cash From Financing Activities -700.0K 5.900M -100.0K
Net Change In Cash 45.60M -28.00M -13.70M
YoY Change -432.85% 113.74% -275.64%
FREE CASH FLOW
Cash From Operating Activities $35.10M $30.40M $48.40M
Capital Expenditures -$400.0K -$700.0K -$100.0K
Free Cash Flow $35.50M $31.10M $48.50M
YoY Change -26.8% -19.85% 123.5%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001088856
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
CY2019Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
us-gaap:ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-50679
dei Entity Registrant Name
EntityRegistrantName
CORCEPT THERAPEUTICS INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
77-0487658
dei Entity Address Address Line1
EntityAddressAddressLine1
149 Commonwealth Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Menlo Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94025
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
327-3270
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Trading Symbol
TradingSymbol
CORT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
116172927 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
30560000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31269000 USD
CY2020Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
398233000 USD
CY2019Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
244693000 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21957000 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
19928000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
4817000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
7926000 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6044000 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
463493000 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
307358000 USD
CY2020Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12075000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2993000 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3446000 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1311000 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1050000 USD
CY2020Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
15425000 USD
CY2019Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
39352000 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
5010000 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3448000 USD
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
33818000 USD
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
45677000 USD
CY2020Q3 us-gaap Assets
Assets
534125000 USD
CY2019Q4 us-gaap Assets
Assets
412312000 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6510000 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
7537000 USD
CY2020Q3 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
15532000 USD
CY2019Q4 cort Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
6477000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18972000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2034000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1558000 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
43048000 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38841000 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
997000 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000 USD
CY2020Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
400000 USD
CY2019Q4 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
386000 USD
CY2020Q3 us-gaap Liabilities
Liabilities
44445000 USD
CY2019Q4 us-gaap Liabilities
Liabilities
41130000 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
121000 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
120000 USD
CY2020Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
496489000 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
457060000 USD
CY2020Q3 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
63969000 USD
CY2019Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
62704000 USD
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
577000 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
261000 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
56462000 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-23555000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
489680000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
534125000 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
412312000 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
86327000 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
81505000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
268139000 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
218591000 USD
CY2020Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1216000 USD
CY2019Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1451000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4328000 USD
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
4068000 USD
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33869000 USD
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22805000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86489000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
64705000 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
26523000 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
24245000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
79630000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73228000 USD
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
61608000 USD
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
48501000 USD
us-gaap Costs And Expenses
CostsAndExpenses
170447000 USD
us-gaap Costs And Expenses
CostsAndExpenses
142001000 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
24719000 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
33004000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
97692000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
76590000 USD
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
622000 USD
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1348000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3103000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3626000 USD
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
25341000 USD
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
34352000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
100795000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
80216000 USD
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3716000 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8012000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20778000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15416000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
21625000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
us-gaap Net Income Loss
NetIncomeLoss
80017000 USD
us-gaap Net Income Loss
NetIncomeLoss
64800000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
109000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
1000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-81000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-123000 USD
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-347000 USD
CY2019Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-2000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
259000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
389000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
84000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
57000 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5000 USD
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
21362000 USD
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
26333000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
80333000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
65184000 USD
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115734000 shares
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113875000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115107000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114349000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124464000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121762000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123337000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122478000 shares
us-gaap Profit Loss
ProfitLoss
80017000 USD
us-gaap Profit Loss
ProfitLoss
64800000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
25109000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
21703000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11778000 USD
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
11731000 USD
us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
404000 USD
us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
1413000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
447000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
474000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1228000 USD
cort Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
1136000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-148000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2029000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4817000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-694000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
654000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1882000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
58000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1562000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
100000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-988000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2424000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
9055000 USD
cort Increase Decrease In Accrued Clinical Expenses
IncreaseDecreaseInAccruedClinicalExpenses
600000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-4315000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2207000 USD
cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1205000 USD
cort Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1108000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
116899000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
87663000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
807000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
953000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
193418000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
168445000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
323094000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
223331000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-130483000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-55839000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
13240000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
275882000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
6643000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
275000 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
30975000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
90000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
4169000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12875000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-28501000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-709000 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3323000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
31269000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
41625000 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30560000 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
44948000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
900000 USD
cort Shares Repurchased In Net Settlement Of Cashless Option Exercise
SharesRepurchasedInNetSettlementOfCashlessOptionExercise
931000 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
775000 USD
cort Non Cash Transaction Recognition Of Right Of Use Asset And Lease Liability
NonCashTransactionRecognitionOfRightOfUseAssetAndLeaseLiability
1878000 USD
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3366000 USD
CY2019Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
5100000 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6724000 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
164000 USD
CY2019Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
13555000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
18274000 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
285755000 USD
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1514000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7791000 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
227000 USD
CY2019Q2 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
17420000 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
20186000 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
298053000 USD
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2697000 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7293000 USD
CY2019Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-7000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
334376000 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
334376000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
371182000 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
480000 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7988000 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
49000 USD
CY2020Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
275000 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
30065000 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
409489000 USD
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7639000 USD
CY2020Q2 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
835000 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8548000 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
530000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
28327000 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
453698000 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6020000 USD
CY2020Q3 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
155000 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8755000 USD
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-263000 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
489680000 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
21625000 USD
cort Number Of Series Of Selective Cortisol Modulators
NumberOfSeriesOfSelectiveCortisolModulators
4 series
CY2020Q3 us-gaap Prepaid Taxes
PrepaidTaxes
1800000 USD
CY2020Q3 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
1516000 USD
CY2019Q4 cort Inventory Raw Materials Current And Noncurrent
InventoryRawMaterialsCurrentAndNoncurrent
1389000 USD
CY2020Q3 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
9284000 USD
CY2019Q4 cort Inventory Work In Process Current And Noncurrent
InventoryWorkInProcessCurrentAndNoncurrent
10086000 USD
CY2020Q3 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
6092000 USD
CY2019Q4 cort Inventory Finished Goods Current And Noncurrent
InventoryFinishedGoodsCurrentAndNoncurrent
5930000 USD
CY2020Q3 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
16892000 USD
CY2019Q4 cort Inventory Current Noncurrent
InventoryCurrentNoncurrent
17405000 USD
CY2020Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
12075000 USD
CY2019Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
11981000 USD
CY2020Q3 us-gaap Inventory Net
InventoryNet
4817000 USD
CY2019Q4 us-gaap Inventory Net
InventoryNet
5424000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
3087000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
2378000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1776000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
1328000 USD
CY2020Q3 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1311000 USD
CY2019Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
1050000 USD
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
12331000 USD
CY2020Q3 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
8972000 USD
CY2019Q4 cort Accrued Government Rebate Current
AccruedGovernmentRebateCurrent
8209000 USD
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
7671000 USD
CY2020Q3 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
876000 USD
CY2019Q4 us-gaap Accrued Marketing Costs Current
AccruedMarketingCostsCurrent
1087000 USD
CY2020Q3 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
611000 USD
CY2019Q4 cort Accrued Legal Fees Current
AccruedLegalFeesCurrent
491000 USD
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
421000 USD
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
367000 USD
CY2020Q3 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
172000 USD
CY2019Q4 cort Accrued Manufacturing Costs
AccruedManufacturingCosts
33000 USD
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
0 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
472000 USD
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
249000 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
279000 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
18972000 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23269000 USD
CY2020Q3 cort Deposits For Clinical Trials
DepositsForClinicalTrials
4800000 USD
CY2019Q4 cort Deposits For Clinical Trials
DepositsForClinicalTrials
3300000 USD
CY2020Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
434722000 USD
CY2019Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
302506000 USD
CY2020Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
1600000 USD
CY2019Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
1000000.0 USD
cort Marketable Securities Maximum Maturity Period
MarketableSecuritiesMaximumMaturityPeriod
P2Y
cort Marketable Securities Weighted Average Maturity Period
MarketableSecuritiesWeightedAverageMaturityPeriod
P5M
cort Long Term Marketable Securities Remaining Maturity
LongTermMarketableSecuritiesRemainingMaturity
P13M
CY2020Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000 USD
us-gaap Operating Lease Expense
OperatingLeaseExpense
1300000 USD
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
514000 USD
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
391000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1326000 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
1160000 USD
CY2020Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q3 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
775000 USD
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1878000 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P18M
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
4.8
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
527000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2109000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
530000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3166000 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
135000 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
3031000 USD
CY2020Q1 cort Short Term Purchase Commitment Minimum Mass Required
ShortTermPurchaseCommitmentMinimumMassRequired
400 kg
CY2020Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 USD
us-gaap Loss Contingency Accrual Provision
LossContingencyAccrualProvision
0 USD
cort Number Of Stock Option Plans
NumberOfStockOptionPlans
2 stock_option_plan
CY2020Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
600000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1700000 shares
CY2019Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500000 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2300000 shares
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
21625000 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
26340000 USD
CY2020Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
53000 USD
CY2019Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
22000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
182000 USD
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
105000 USD
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
8755000 USD
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
7293000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
25291000 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
21808000 USD
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113875000 shares
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.19
us-gaap Net Income Loss
NetIncomeLoss
80017000 USD
us-gaap Net Income Loss
NetIncomeLoss
64800000 USD
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115734000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
115107000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
114349000 shares
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8730000 shares
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
7887000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8230000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
8129000 shares
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
124464000 shares
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
121762000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
123337000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
122478000 shares
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.23
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.70
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.57
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.17
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.53
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
26000000.0 shares
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
24100000 shares
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.65
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3700000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
20800000 USD
CY2020Q3 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1000000.0 USD
us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
2100000 USD
CY2020Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-1800000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-11800000 USD
CY2020Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2000000.0 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
9000000.0 USD
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
8000000.0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
15400000 USD
CY2019Q3 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-5900000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-11700000 USD
CY2019Q3 us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
2100000 USD
us-gaap State And Local Income Tax Expense Benefit Continuing Operations
StateAndLocalIncomeTaxExpenseBenefitContinuingOperations
3700000 USD

Files In Submission

Name View Source Status
0001628280-20-015376-index-headers.html Edgar Link pending
0001628280-20-015376-index.html Edgar Link pending
0001628280-20-015376.txt Edgar Link pending
0001628280-20-015376-xbrl.zip Edgar Link pending
cort-20200930.htm Edgar Link pending
cort-20200930.xsd Edgar Link pending
cort-20200930_cal.xml Edgar Link unprocessable
cort-20200930_def.xml Edgar Link unprocessable
cort-20200930_htm.xml Edgar Link completed
cort-20200930_lab.xml Edgar Link unprocessable
cort-20200930_pre.xml Edgar Link unprocessable
cort93020ex311.htm Edgar Link pending
cort93020ex312.htm Edgar Link pending
cort93020ex321.htm Edgar Link pending
cort93020ex322.htm Edgar Link pending
cortex101sixthamendmen.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
image_01a.jpg Edgar Link pending
image_11a.jpg Edgar Link pending
image_21a.jpg Edgar Link pending
image_31a.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending